CPMD CANNAPHARMARX, INC.

CIK 0001081938 17 ready 8-Ks latest January 13, 2026, 6:59 PM ET RSS · JSON

Activity: NORMAL 0 filings / 30d vs 0 baseline

Ready 8-Ks 17

Latest filing January 13, 2026, 6:59 PM ET

Top materiality 0.80

Event mix other_material ×8 · leadership ×5 · m_and_a ×2

Sentiment 4 pos · 2 neg · 11 neu

Executive change recent →

SHENANIGAN SCORE 1 / 7 see the board

Recent 8-K filings for CPMD

Highest-materiality recent filing

CannaPharmaRX announces revocation of cease trade order by BC Securities Commission

December 18, 2025, 6:59 PM ET regulatory materiality 0.80 negative item 8.01 item 9.01

BC Securities Commission revoked failure-to-file cease trade order effective December 12, 2025.
Company faces going concern uncertainty with working capital deficiency of $27,009,769 as of Sep 30, 2025.

Read filing →

January 13, 2026, 6:59 PM ET other material materiality 0.55 neutral item 5.02 item 8.01 item 9.01

Director Rick Orman resigns; CannaPharmaRX exports 250 kg to Israel, plans Q1 shipments and expansion

Director Rick Orman resigned from board effective Jan 8, 2026; no dispute with company.
December 18, 2025, 6:59 PM ET regulatory materiality 0.80 negative item 8.01 item 9.01

CannaPharmaRX announces revocation of cease trade order by BC Securities Commission

BC Securities Commission revoked failure-to-file cease trade order effective December 12, 2025.
October 10, 2025, 7:59 PM ET debt materiality 0.50 neutral item 8.01 item 9.01

CannaPharmaRX enters debt repayment schedules with two key debtholders

Entered letter agreements with payment schedules for outstanding debts to A. Tal and Koze Investments.
May 6, 2025, 7:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

CannaPharmaRX completes first Germany shipment; 4 shipments to Israel done in 2024-2025

First Germany shipment in March 2025: 227.5 kg at avg. 1.94 CAD/gram; 4 Israel shipments totalling 664.4 kg through April 2025.
March 31, 2025, 7:59 PM ET leadership materiality 0.50 neutral item 5.02 ◈ executive_change ×3

CannaPharmaRX appoints Constantine Nkafu as interim CEO, adds two directors

Constantine Nkafu appointed interim CEO and board member; has led operations for past several months.
December 3, 2024, 6:59 PM ET other material materiality 0.40 neutral item 4.01 item 9.01 ◈ Auditor Changes

CannaPharmaRX appoints Barzily & Co. as new independent auditor for FY 2024

Engaged Barzily & Co. as independent registered public accounting firm on November 29, 2024.
November 21, 2024, 6:59 PM ET other material materiality 0.60 negative item 4.01 item 9.01 ◈ Auditor Changes

Auditor GreenGrowth CPAs resigns from CannaPharmaRX effective Nov 14, 2024

GreenGrowth CPAs resigned as auditor effective November 14, 2024.
September 17, 2024, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 ◈ executive_change

CannaPharmaRX CEO Dean Medwid resigns for personal reasons; board searches for successor

Dean Medwid stepped down as CEO effective September 9, 2024, for personal reasons.
February 22, 2024, 6:59 PM ET other material materiality 0.60 positive item 9.01

CannaPharmaRX finalizes multi-million dollar supply agreement with Cantek for Israeli cannabis market

Agreement with Cantek, Israeli medical cannabis distributor, for minimum 1,000 kgs of product annually.
February 16, 2024, 6:59 PM ET other material materiality 0.50 neutral item 1.01 item 9.01 ◈ Material Agreements

CannaPharmaRX enters supply agreement with Cantek for minimum 1,000 kg/year at $2.75 CDN/g

Cantek commits to minimum 1,000 kg of product annually for 3 years at $2.75 CDN/g.
December 6, 2023, 6:59 PM ET M&A materiality 0.70 neutral item 1.01 item 2.01 item 3.02 item 9.01 ◈ M&A Transactions◈ Material Agreements

CannaPharmaRX acquires LTB Management for 33% stake, $3M notes, and warrants

Acquired all Class B interests in LTB Management; total consideration includes convertible preferred stock representing 33% of fully-diluted common (adjustable 28%-45% based on earn-out).
November 13, 2023, 6:59 PM ET other material materiality 0.50 neutral item 4.01 item 9.01 ◈ Auditor Changes ×2

CannaPharmaRX terminates auditor BF Borgers, engages GreenGrowth CPAs

BF Borgers CPA PC terminated as independent auditor effective Nov 6, 2023; served since 2018.
October 13, 2023, 7:59 PM ET leadership materiality 0.50 neutral item 5.02 item 9.01 ◈ executive_change ×2

CannaPharmaRX appoints Oliver Foeste as CFO; John Cassels departs without disagreement

John Cassels replaced as CFO effective Oct 13, 2023; no disagreement with company on operations.
August 28, 2023, 7:59 PM ET leadership materiality 0.40 neutral item 5.02 item 9.01 ◈ executive_change ×3

CannaPharmaRx expands board to five; Branson resigns, Panek and Mindle appointed

Mark Branson resigned from board effective March 23, 2023, not due to any dispute.
June 23, 2023, 7:59 PM ET leadership materiality 0.55 neutral item 5.02 item 9.01 ◈ executive_change ×2

CannaPharmaRX appoints Dean Medwid as CEO; Dominic Colvin steps down

Dominic Colvin stepped down as CEO effective June 1, 2023; no disagreement over operations.
February 16, 2022, 6:59 PM ET M&A materiality 0.75 positive item 7.01 item 9.01

CannaPharmaRx signs LOI to acquire Oklahoma cannabis facility with $21M estimated annual revenue

Signed LOI to purchase 35,000 sq ft operating cannabis facility in Braman, OK; planned expansion to 65,000 sq ft by end of 2022.
July 16, 2021, 7:59 PM ET other material materiality 0.55 positive item 1.01 item 7.01 item 9.01

CannaPharmaRx sells Hanover facility for $2M CAD to reduce debt

Sold Hanover, Ontario facility for $2,000,000 CAD, including 10 acres and 48,800 sq ft of growing space.

Executive changes

Appointed (interim)

Constantine Nkafu

Interim Chief Executive Officer

CPMD · CANNAPHARMARX, INC.

Filed: March 31, 2025, 7:59 PM ET

The Board appointed Constantine Nkafu to serve as the Company’s interim CEO.

Appointed

Elliot Zemel

Director

CPMD · CANNAPHARMARX, INC.

Filed: March 31, 2025, 7:59 PM ET

Messrs. Constantine Nkafu, Company’s interim CEO, and Elliot Zemel, have now been appointed to the Board.

Appointed

Constantine Nkafu

Director

CPMD · CANNAPHARMARX, INC.

Filed: March 31, 2025, 7:59 PM ET

Mr. Nkafu was also appointed to the Company’s Board

Departed

Dean Medwid

Chief Executive Officer

CPMD · CANNAPHARMARX, INC.

Filed: September 17, 2024, 7:59 PM ET

Dean Medwid stepped down as the Chief Executive Officer (“CEO”) of CannaPharmaRX, Inc. (the “Company”) for personal reasons.

Appointed

Oliver Foeste

Chief Financial Officer

CPMD · CANNAPHARMARX, INC.

Effective: 2023-10-13
Filed: October 13, 2023, 7:59 PM ET

Effective October 13, 2023, our Board of Directors has determined to appoint Oliver Foeste as Chief Financial Officer.

Departed

John Cassels

Chief Financial Officer

CPMD · CANNAPHARMARX, INC.

Effective: 2023-10-13
Successor: Oliver Foeste
Filed: October 13, 2023, 7:59 PM ET

Effective October 13, 2023, John Cassels is being replaced as the Chief Financial Officer (“CFO”) of CannPharmaRX, Inc.

Departed

Mark Branson

Director

CPMD · CANNAPHARMARX, INC.

Effective: 2023-03-23
Successor: Adam Mindle and Anthony Michael Panek
Filed: August 28, 2023, 7:59 PM ET

On March 23, 2023, Mark Branson informed the Board of Directors (the “Board”) of CannaPharmaRx, Inc. (the “Company”) that he intends to resign as a member of the Board effective immediately.

Appointed

Anthony Michael Panek

Director

CPMD · CANNAPHARMARX, INC.

Effective: 2023-08-15
Filed: August 28, 2023, 7:59 PM ET

On August 15th, 2023, the remaining members of the Board appointed Messrs. Adam Mindle and Anthony Michael Panek as members of the Board

Appointed

Adam Mindle

Director

CPMD · CANNAPHARMARX, INC.

Effective: 2023-08-15
Filed: August 28, 2023, 7:59 PM ET

On August 15th, 2023, the remaining members of the Board appointed Messrs. Adam Mindle and Anthony Michael Panek as members of the Board

Appointed

Dean Medwid

Chief Executive Officer

CPMD · CANNAPHARMARX, INC.

Effective: 2023-06-01
Filed: June 23, 2023, 7:59 PM ET

On June 1, 2023, the Company’s Board of Directors appointed Dean Medwid as Chief Executive Officer.

Departed

Dominic Colvin

Chief Executive Officer

CPMD · CANNAPHARMARX, INC.

Effective: 2023-06-01
Successor: Dean Medwid
Filed: June 23, 2023, 7:59 PM ET

Dominic Colvin stepped down as the Chief Executive Officer (“CEO”) of CannPharmaRX, Inc. (the “Company”) effective June 1, 2023.

Materiality & sentiment trend

Max materiality 0.80 · Median 0.55 · Most common event other_material

4 positive 2 negative 11 neutral

source · CPMD on sec.gov